MCID: TMP003
MIFTS: 67

Temporal Arteritis

Categories: Rare diseases, Oral diseases, Cardiovascular diseases, Nephrological diseases, Bone diseases, Neuronal diseases, Muscle diseases

Aliases & Classifications for Temporal Arteritis

MalaCards integrated aliases for Temporal Arteritis:

Name: Temporal Arteritis 53 12 49 50 55 14 69
Polymyalgia Rheumatica 53 12 72 55 36 51 40 41 14 69
Giant Cell Arteritis 53 12 72 49 50 55 36 40 41 69
Cranial Arteritis 53 49 50 69
Rhizomelic Pseudopolyarthritis 55 69
Horton Disease 72 55
Gca 53 49
Horton's Giant Cell Arteritis 49
Polymyalgia Rheumatica [dup] 12
Horton's Temporal Arteritis 49
Giant Cell Arteritis; Gca 53
Giant Cell Arteritis Nos 12
Arteritis Temporalis 49
Arteritis Cranialis 49
Horton's Arteritis 49
Horton’s Syndrome 49
Horton's Disease 12
Horton’s Disease 49

Characteristics:

Orphanet epidemiological data:

55
giant cell arteritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Germany),1-5/10000 (United Kingdom),1-5/10000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
temporal arteritis:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Temporal Arteritis

MedlinePlus : 40 Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no single test to diagnose giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Temporal Arteritis, also known as polymyalgia rheumatica, is related to retinal vasculitis and vasculitis, and has symptoms including ataxia, arthralgia and fatigue. An important gene associated with Temporal Arteritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Prednisone and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, tongue and skin, and related phenotype is immune system.

NIH Rare Diseases : 49 Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but other arteries can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow. Signs and symptoms may include a throbbing headache on one side of the head or the back of the head, tenderness of the scalp, various symptoms that feel like the flu, and/or problems with eyesight. The cause of GCA is still being studied, but it is thought to involve the immune system mistakenly attacking the artery walls. Several genetic and environmental factors may increase a person's risk to develop GCA. Complications of GCA may include permanent vision loss or a stroke, so treatment is important and may include corticosteroids and/or other medications that suppress the immune system. GCA may develop with or after another inflammatory disorder known as polymyalgia rheumatica.  Last updated: 10/5/2017

NINDS : 50 Vasculitis is inflammation of blood vessels, which includes the veins, arteries, and capillaries. It occurs when the immune system mitakenly attacks a blood vessel. Vasculitis can also be caused by other immune system disease, an allergic reaction to medicines or toxins, and by certain blood cancers that trigger an immune system reaction. The resulting reduced blood flow can permanently damage the brain, spinal cord, peripheral nervous system, and other organs and tissue. Some forms of vasculitis affect a particular organ, whie others may affect many organs at the same time. Symptoms include headaches (especially a headache that doesn’t go away), fever, weight loss, confusion or forgetfulness leading to dementia, swelling of the brain, pain, vision problems, trouble speaking or understanding, muscle weakness and paralysis, and seizures. Some of the better understood vasculitis syndromes are temporal arteritis (also called giant cell arteritis or cranial arteritis--a chronic inflammatory disorder of large blood vessels) and Takayasu’s disease, which affects larger aortas and may cause stoke.

Wikipedia : 72 Giant-cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of blood vessels.... more...

Description from OMIM: 187360

Related Diseases for Temporal Arteritis

Diseases in the Temporal Arteritis family:

Juvenile Temporal Arteritis

Diseases related to Temporal Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 307)
# Related Disease Score Top Affiliating Genes
1 retinal vasculitis 32.2 APOH CCL2
2 vasculitis 30.5 APOH CCL2 CD40LG CRP
3 polyarteritis nodosa 30.2 APOH CRP IL6
4 endocarditis 30.1 APOH CRP IL6
5 aortitis 30.0 CRP SMUG1
6 chlamydia 30.0 CD40LG CRP IFNG IL6
7 purpura 30.0 APOH CD40LG CRP
8 infective endocarditis 29.7 APOH CRP IL6
9 retinal vein occlusion 29.6 APOH CCL2 IL6
10 arteriosclerosis 29.6 CCL2 CRP IL6
11 periodontitis 29.5 CCL2 CRP IFNG IL6
12 ulcerative colitis 29.4 CRP IFNG IL6
13 wegener granulomatosis 29.4 CRP IFNG IL6 PTPN22
14 pneumonia 29.1 CCL2 CCL5 CD40LG CRP IL6
15 radiculopathy 29.1 CCL2 CCL5 IL6
16 arthritis 28.9 CCL2 HLA-DRB1 IFNG IL1RN IL6 PTPN22
17 interstitial lung disease 28.8 CCL2 CCL5 IFNG IL6
18 myocardial infarction 28.7 CCL2 CCL5 CD40LG CRP IL6
19 rheumatoid arthritis 27.4 CCL2 CCL5 CD40LG CRP HLA-DRB1 IFNG
20 bone inflammation disease 27.2 CCL2 CD40LG CRP HLA-DRB1 IFNG IL1RN
21 juvenile temporal arteritis 12.6
22 rhizomelic pseudopolyarthritis 12.4
23 nonarteritic anterior ischemic optic neuropathy 11.5
24 vasculitis syndromes of the central and peripheral nervous systems 11.1
25 acromesomelic dysplasia 11.0
26 acalculous cholecystitis 10.5 CD40LG CRP
27 mononeuritis multiplex 10.5 CD40LG CRP
28 borderline leprosy 10.5 APOH CD40LG
29 viral exanthem 10.5 APOH CD40LG
30 livedoid vasculopathy 10.5 APOH CD40LG
31 cat-scratch disease 10.5 CD40LG IFNG
32 erythema infectiosum 10.5 APOH CD40LG
33 sporotrichosis 10.5 CD40LG IFNG
34 acute maxillary sinusitis 10.5 CD40LG CRP
35 berylliosis 10.5 HLA-DRB1 IFNG
36 ovarian squamous cell carcinoma 10.5 CRP SMUG1
37 cardiovascular syphilis 10.5 CD40LG SMUG1
38 chronic beryllium disease 10.5 HLA-DRB1 IFNG
39 neuronitis 10.4 CD40LG TNFRSF10A
40 autoimmune addison disease 10.4 HLA-DRB1 PTPN22
41 rheumatoid factor-negative juvenile idiopathic arthritis 10.4 HLA-DRB1 PTPN22
42 japanese spotted fever 10.4 CD40LG CRP
43 pelvic inflammatory disease 10.4 CCL2 CD40LG CRP
44 pleurisy 10.4 CCL2 CRP IFNG
45 tolosa-hunt syndrome 10.4 CD40LG SMUG1
46 cold agglutinin disease 10.4 CRP IL6
47 systemic scleroderma 10.4 CD40LG CRP IFNG
48 geniculate herpes zoster 10.4 CD40LG TNFRSF10A
49 diabetic foot ulcers 10.3 CRP IL6
50 mumps 10.3 CD40LG HLA-DRB1 IFNG

Comorbidity relations with Temporal Arteritis via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Aortic Valve Disease 1 Bronchitis
Cerebral Arteritis Chronic Myocardial Ischemia
Conn's Syndrome Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Ischemic Heart Disease
Mitral Valve Disease Nonarteritic Anterior Ischemic Optic Neuropathy
Optic Neuritis Osteoporosis
Polymyositis Premature Ovarian Failure 7
Rheumatoid Arthritis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Temporal Arteritis:



Diseases related to Temporal Arteritis

Symptoms & Phenotypes for Temporal Arteritis

Symptoms via clinical synopsis from OMIM:

53
Eyes:
blindness
retinal arteritis

Lab:
elevated sedimentation rate

Vascular:
temporal arteritis
giant cell arteritis
polymyalgia rheumatica (pmr)

Misc:
response to adrenal glucocorticoids


Clinical features from OMIM:

187360

Human phenotypes related to Temporal Arteritis:

55 31 (show top 50) (show all 59)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001251
2 arthralgia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002829
3 fatigue 55 31 hallmark (90%) Very frequent (99-80%) HP:0012378
4 myalgia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003326
5 fever 55 31 hallmark (90%) Very frequent (99-80%) HP:0001945
6 headache 55 31 hallmark (90%) Very frequent (99-80%) HP:0002315
7 vertigo 55 31 occasional (7.5%) Occasional (29-5%) HP:0002321
8 abdominal pain 55 31 occasional (7.5%) Occasional (29-5%) HP:0002027
9 joint stiffness 55 31 hallmark (90%) Very frequent (99-80%) HP:0001387
10 muscle weakness 55 31 occasional (7.5%) Occasional (29-5%) HP:0001324
11 amaurosis fugax 55 31 occasional (7.5%) Occasional (29-5%) HP:0100576
12 recurrent pharyngitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0100776
13 ophthalmoparesis 55 31 frequent (33%) Frequent (79-30%) HP:0000597
14 ptosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000508
15 nystagmus 55 31 occasional (7.5%) Occasional (29-5%) HP:0000639
16 diplopia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000651
17 hyperhidrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000975
18 sudden cardiac death 55 31 occasional (7.5%) Occasional (29-5%) HP:0001645
19 arthritis 55 31 frequent (33%) Frequent (79-30%) HP:0001369
20 visual impairment 55 31 frequent (33%) Frequent (79-30%) HP:0000505
21 optic atrophy 55 31 occasional (7.5%) Occasional (29-5%) HP:0000648
22 renal insufficiency 55 31 occasional (7.5%) Occasional (29-5%) HP:0000083
23 weight loss 55 31 hallmark (90%) Very frequent (99-80%) HP:0001824
24 abnormality of the pleura 55 31 occasional (7.5%) Occasional (29-5%) HP:0002103
25 alopecia 55 31 frequent (33%) Frequent (79-30%) HP:0001596
26 aortic dissection 55 31 occasional (7.5%) Occasional (29-5%) HP:0002647
27 skin ulcer 55 31 occasional (7.5%) Occasional (29-5%) HP:0200042
28 visual field defect 55 31 occasional (7.5%) Occasional (29-5%) HP:0001123
29 anorexia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002039
30 cerebral ischemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002637
31 paresthesia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003401
32 hematuria 55 31 occasional (7.5%) Occasional (29-5%) HP:0000790
33 diabetes insipidus 55 31 occasional (7.5%) Occasional (29-5%) HP:0000873
34 visual loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0000572
35 conductive hearing impairment 55 31 occasional (7.5%) Occasional (29-5%) HP:0000405
36 epistaxis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000421
37 pericarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001701
38 meningitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001287
39 cough 55 31 occasional (7.5%) Occasional (29-5%) HP:0012735
40 vasculitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002633
41 hepatic failure 55 31 occasional (7.5%) Occasional (29-5%) HP:0001399
42 arterial thrombosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0004420
43 mediastinal lymphadenopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0100721
44 gastrointestinal infarctions 55 31 occasional (7.5%) Occasional (29-5%) HP:0005244
45 chewing difficulties 55 31 hallmark (90%) Very frequent (99-80%) HP:0005216
46 gangrene 55 31 occasional (7.5%) Occasional (29-5%) HP:0100758
47 glossitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000206
48 elevated erythrocyte sedimentation rate 55 31 frequent (33%) Frequent (79-30%) HP:0003565
49 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0011658
50 abdominal aortic aneurysm 55 31 occasional (7.5%) Occasional (29-5%) HP:0005112

UMLS symptoms related to Temporal Arteritis:


edema, chest pain, angina pectoris, myalgia, muscle weakness, sciatica, pruritus, muscle spasticity, muscle rigidity, muscle cramp, exanthema, back pain

MGI Mouse Phenotypes related to Temporal Arteritis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 CCL2 CCL5 CD40LG CRP IFNG IL1RN

Drugs & Therapeutics for Temporal Arteritis

Drugs for Temporal Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
3 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
4 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
5 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
6 Hormones Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Omega 3 Fatty Acid Nutraceutical Phase 4
9
Infliximab Approved Phase 3,Phase 2 170277-31-3
10
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
12
Hydroxychloroquine Approved Phase 3 118-42-3 3652
13
Adalimumab Approved Phase 3 331731-18-1 16219006
14
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
15
Etanercept Approved, Investigational Phase 3 185243-69-0
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
18
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
22 Antirheumatic Agents Phase 3,Phase 2
23 Dermatologic Agents Phase 3,Phase 2,Phase 1
24 Gastrointestinal Agents Phase 3,Phase 2
25 Anti-Infective Agents Phase 3
26 Antiemetics Phase 2, Phase 3
27 Autonomic Agents Phase 2, Phase 3
28 Methylprednisolone acetate Phase 2, Phase 3
29 Methylprednisolone Hemisuccinate Phase 2, Phase 3
30 Neuroprotective Agents Phase 2, Phase 3
31 Peripheral Nervous System Agents Phase 2, Phase 3
32 Prednisolone acetate Phase 2, Phase 3
33 Prednisolone hemisuccinate Phase 2, Phase 3
34 Prednisolone phosphate Phase 2, Phase 3
35 Protective Agents Phase 2, Phase 3
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
37 Pharmaceutical Solutions Phase 3
38 Antimalarials Phase 3
39 Antiparasitic Agents Phase 3
40 Antiprotozoal Agents Phase 3
41 Bone Density Conservation Agents Phase 3
42 Hydroxycholecalciferols Phase 3
43 Micronutrients Phase 3
44 Trace Elements Phase 3
45 Vitamins Phase 3
46 Analgesics Phase 3
47 Analgesics, Non-Narcotic Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Antimetabolites Phase 3,Phase 2
50 Antimetabolites, Antineoplastic Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 70)

# Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
3 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
4 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
5 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
6 Hydroxychloroquine in Giant Cell Arteritis Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
7 HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
8 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
9 Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
10 Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
11 A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
12 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
13 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Active, not recruiting NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
14 Giant Cell Arteritis and Anakinra Trial Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
15 An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Not yet recruiting NCT03202368 Phase 3 Tocilizumab
16 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Terminated NCT02531633 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
17 A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
18 A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
19 Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Withdrawn NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
20 Tocilizumab for Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
21 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed NCT00556439 Phase 2 Abatacept;Placebo
22 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/4 weeks
23 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
24 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
25 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
26 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
27 Ustekinumab for the Treatment of Giant Cell Arteritis Recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
28 Baricitinib in Relapsing Giant Cell Arteritis Recruiting NCT03026504 Phase 2 Baricitinib
29 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Terminated NCT00076726 Phase 2 Infliximab
30 Delayed Release Prednisone in PMR Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone
31 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Terminated NCT01364389 Phase 2 AIN457;ACZ885;Prednisone;Placebo
32 MRI Superficial Temporal Artery Completed NCT00188448 Phase 1
33 Diagnostic Study of Temporal Arteritis Unknown status NCT01130857
34 Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis Unknown status NCT00361192 Early Phase 1
35 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
36 Study of the T CD8 Immune Response in Horton's Disease Unknown status NCT02158208
37 Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica Unknown status NCT00982332 Betamethasone;isotonic sodium chloride solution (placebo)
38 Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD) Unknown status NCT02065297
39 FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment Completed NCT03285945 PET3;PET10
40 Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA Completed NCT03409913
41 Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) Completed NCT00974883
42 Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis Completed NCT01795456
43 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
44 Impact of Vasculitis on Employment and Income Completed NCT02476292
45 Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica Completed NCT02888496 tocilizumab
46 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
47 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
48 Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS Completed NCT02042092
49 Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica Completed NCT00847236
50 Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis Recruiting NCT00315497

Search NIH Clinical Center for Temporal Arteritis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: polymyalgia rheumatica

Genetic Tests for Temporal Arteritis

Anatomical Context for Temporal Arteritis

MalaCards organs/tissues related to Temporal Arteritis:

38
Testes, Tongue, Skin, Brain, Eye, Spinal Cord, Bone

Publications for Temporal Arteritis

Articles related to Temporal Arteritis:

(show top 50) (show all 1120)
# Title Authors Year
1
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
2
The potential for dual pathology in temporal arteritis. ( 29186538 )
2018
3
Studies on the Histopathology of Temporal Arteritis. ( 28275606 )
2017
4
Clinical correlation of biopsy results in patients with temporal arteritis. ( 29451658 )
2017
5
Metaplastic ossification of the temporal artery with osteoclast-like giant cells: a mimicker of giant cell (temporal) arteritis. ( 28315516 )
2017
6
The acupuncture therapeutic approach in temporal arteritis vasculitis: A case report. ( 29436372 )
2017
7
Identification of herpes zoster associated temporal arteritis among cases of giant cell arteritis. ( 29294312 )
2017
8
Stroke and temporal arteritis: A study of 6 cases. ( 28869044 )
2017
9
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? ( 28899801 )
2017
10
Proliferative Synovitis of the Shoulder Bursae is a Key Feature for Discriminating Elderly Onset Rheumatoid Arthritis Mimicking Polymyalgia Rheumatica From Polymyalgia Rheumatica. ( 29242702 )
2017
11
Amyloidosis Mimicking Temporal Arteritis in Multiple Myeloma. ( 29157426 )
2017
12
Not Every Case of Temporal Arteritis Is Giant Cell Arteritis. Microscopic Polyangiitis Involving the Temporal Artery: A Case Report and Review of the Literature. ( 29293114 )
2017
13
Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. ( 28583280 )
2017
14
Giant Cell (Temporal) Arteritis with Persistent Bilateral Sensorineural Hearing Loss - A Likely Consequence of Delayed Institution of Glucocorticoid Therapy. ( 29186088 )
2017
15
Juvenile temporal arteritis with eosinophilia associated with systemic sclerosis. ( 27401371 )
2016
16
Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review. ( 26769433 )
2016
17
Myalgias and Myopathies: Polymyalgia Rheumatica and Giant Cell Arteritis. ( 26734832 )
2016
18
Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. ( 27133763 )
2016
19
Response to: 'A relationship between extracapsular involvement and response to steroid treatment in polymyalgia rheumatica: too soon to conclude?' by Yang et al. ( 26819098 )
2016
20
Are the New ACR/EULAR Criteria the Ultimate Answer for Polymyalgia Rheumatica Classification? ( 27134265 )
2016
21
Giant cell or temporal arteritis? ( 28691446 )
2016
22
Temporal Arteritis With Arteritic Anterior Ischemic Optic Neuropathy is Bilateral Until Proven Otherwise: Response. ( 27855129 )
2016
23
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) in Polymyalgia Rheumatica. ( 27342326 )
2016
24
The Temporal Arteritis Proforma: Should cough be included? ( 27592336 )
2016
25
Does Viking ancestry influence the distribution of polymyalgia rheumatica and giant cell arteritis in Poland? ( 27088874 )
2016
26
VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. ( 26688577 )
2016
27
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. ( 26929219 )
2016
28
Temporal arteritis with erythrocyte sedimentation rate <50 mm/h: a clinical reminder. ( 26966355 )
2016
29
Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth, Clostridium difficile infection and polymyalgia rheumatica. ( 26818813 )
2016
30
A Case of Frontal Fibrosing Alopecia in a Patient with Primary Biliary Cirrhosis and Polymyalgia Rheumatica. ( 27843932 )
2016
31
Tocilizumab for polymyalgia rheumatica: a first or second line? ( 27075011 )
2016
32
Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set. ( 27843375 )
2016
33
Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. ( 26753600 )
2016
34
Polymyalgia Rheumatica and Giant Cell Arteritis: A Review Article. ( 27156261 )
2016
35
Recent advances in the diagnosis and treatment of polymyalgia rheumatica. ( 27079756 )
2016
36
Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. ( 26786818 )
2016
37
Extracranial cutaneous manifestation of temporal arteritis--a case of erythematous plaques on the legs. ( 26713645 )
2016
38
Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. ( 27107429 )
2016
39
Is All Inflammation within Temporal Artery Biopsies Temporal Arteritis? ( 27445262 )
2016
40
A Prospective Open Label Phase IIa Trial of Tocilizumab In the Treatment of Polymyalgia Rheumatica. ( 27159185 )
2016
41
Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study. ( 26724323 )
2016
42
A relationship between extracapsular involvement and response to steroid treatment in polymyalgia rheumatica: too soon to conclude? ( 26698848 )
2016
43
Bilateral Blindness in a Patient With Temporal Arteritis After Wisdom Tooth Extraction. ( 26854772 )
2016
44
Association of Remitting Seronegative Symmetrical Synovitis with Pitting Edema, Polymyalgia Rheumatica, and Adenocarcinoma of the Prostate. ( 26839040 )
2016
45
Hypertrophic Pachymeningitis as a Potential Cause of Headache Associated with Temporal Arteritis. ( 26935376 )
2016
46
Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study. ( 26834222 )
2016
47
Preserved Visual Acuity in Anterior Ischemic Optic Neuropathy Secondary to Giant Cell (temporal) Arteritis. ( 26958148 )
2016
48
When a temporal artery biopsy reveals a diagnosis other than temporal arteritis: eosinophilic granulomatosis with polyangiitis. ( 27316282 )
2016
49
Thin-section chest CT findings in polymyalgia rheumatica: a comparison between with and without rheumatoid arthritis. ( 27133672 )
2016
50
Sterno-clavicular involvement in polymyalgia rheumatica. ( 26494596 )
2015

Variations for Temporal Arteritis

Expression for Temporal Arteritis

Search GEO for disease gene expression data for Temporal Arteritis.

Pathways for Temporal Arteritis

Pathways related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 CCL2 CCL5 CD40LG CRP HLA-DRB1 IFNG
2
Show member pathways
13.09 CCL2 CCL5 CD40LG HLA-DRB1 IFNG IL1RN
3
Show member pathways
13.08 CCL2 CCL5 CD40LG IL6 PTPN22 TNFRSF10A
4
Show member pathways
12.54 CCL2 CCL5 HLA-DRB1 IFNG IL6 TNFRSF10A
5
Show member pathways
12.31 CCL2 CCL5 IFNG IL6
6 12.31 CCL2 CCL5 CD40LG IFNG IL1RN PTPN22
7 11.81 CCL2 IFNG IL6
8
Show member pathways
11.77 CCL2 CCL5 CRP IFNG IL6 SERPINA3
9 11.76 CCL2 CCL5 IL6
10 11.47 CCL2 CCL5 IL6
11
Show member pathways
11.45 CD40LG IFNG IL6
12 11.25 CCL2 CCL5 IL1RN IL6
13 11.15 CCL2 CD40LG IFNG IL6
14 11.06 HLA-DRB1 IFNG IL6
15 10.99 CCL2 CCL5 CD40LG IL6
16 10.98 CCL2 CCL5 HLA-DRB1 IFNG IL6
17 10.85 CCL2 SERPINA3
18 10.85 CRP IL6

GO Terms for Temporal Arteritis

Cellular components related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 APOH CCL2 CCL5 CD40LG CRP IFNG
2 extracellular space GO:0005615 9.28 APOH CCL2 CCL5 CD40LG CRP IFNG

Biological processes related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.84 CRP IFNG IL6 PTPN22
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 CCL5 IFNG IL6
3 positive regulation of T cell proliferation GO:0042102 9.63 CCL5 CD40LG IL6
4 regulation of receptor activity GO:0010469 9.63 CCL2 CCL5 CD40LG IFNG IL1RN IL6
5 humoral immune response GO:0006959 9.61 CCL2 IFNG IL6
6 immune response GO:0006955 9.56 CCL2 CCL5 CD40LG HLA-DRB1 IFNG IL1RN
7 monocyte chemotaxis GO:0002548 9.54 CCL2 CCL5 IL6
8 positive regulation of JAK-STAT cascade GO:0046427 9.52 CCL5 IL6
9 macrophage chemotaxis GO:0048246 9.51 CCL2 CCL5
10 acute-phase response GO:0006953 9.5 CRP IL6 SERPINA3
11 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
12 lipopolysaccharide-mediated signaling pathway GO:0031663 9.43 CCL2 CCL5 PTPN22
13 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.4 IL1RN IL6
14 inflammatory response GO:0006954 9.23 CCL2 CCL5 CD40LG CRP IL1RN IL6

Molecular functions related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 APOH CCL2 CCL5 CD40LG CDK9 CRP
2 cytokine activity GO:0005125 9.1 CCL2 CCL5 CD40LG IFNG IL1RN IL6

Sources for Temporal Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....